CREGG
Club de Réflexion des Cabinets
et Groupes d'Hépato-Gastroentérologie

LA MINUTE HÉPATO

L'AASLD et L'EASL en direct et en quelques minutes chaque jour

CHC avancé :
le traitement de référence

Schéma de l'étude de Phase III IMbrave 150



(Open label)

Co-primary endpoints

- OS
- IRF-assessed PFS per RECIST 1.1

Key secondary efficacy endpoints

- IRF-assessed PFS per HCC mRECIST
- IRF-assessed ORR per RECIST 1.1 and HCC mRECIST
- IRF-assessed DOR per RECIST 1.1 and HCC mRECIST

Abs. 1060; Andrew Zhu et al. AASLD 2021

Courbes de survie globale





Abs. 1060; Andrew Zhu et al. AASLD 2021

Effets indésirables grade 3/4 survenant chez ≥ 5%, n (%)

	Non-viral population		HBV population		HCV population	
	Atezo + Bev (n=98)	Sorafenib (n=52)	Atezo + Bev (n=162)	Sorafenib (n=71)	Atezo + Bev (n=69)	Sorafenib (n=33)
Hypertension	18 (18)	5 (10)	24 (15)	9 (13)	14 (20)	5 (15)
Augmentation Bilirubine	7 (7)	3 (6)	5 (3)	3 (4)	1 (1)	4 (12)
Diarrhée	5 (5)	5 (10)	4 (2)	3 (4)	2 (3)	0
Ascite	5 (5)	3 (6)	6 (4)	0	1 (1)	0
Augmentation ASAT	4 (4)	5 (10)	11 (7)	3 (4)	11 (16)	1 (3)
Syndrome main-pied	0	2 (4)	0	5 (7)	0	6 (18)

Abs. 1060; Andrew Zhu et al. AASLD 2021